This New Real Estate Investment Offering Comes With 27.4% Targeted Annual Return

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

CrowdStreet, a real estate investing platform, is opening up a new commercial real estate investment opportunity for a life sciences campus development in the Boston metropolitan area.

The new investment offering, 216 New Boston Lab Development, will fund the acquisition and redevelopment of an existing 14.68-acre parcel that will have two buildings totaling 302,721 square feet of laboratory and current good manufacturing practice (cGMP) space. 

The deal sponsor expects the project to take 27 months to complete, and anticipates having the entire project fully leased before it’s finished due to the high demand for laboratory and cGMP space in the market. 

Investment Highlights

Targeted Investor IRR: 27.4%

Targeted Equity Multiple: 2.8x

Targeted Average Cash Yield: 1.7%

Targeted Investment Period: 5 years

Deal Sponsor

The deal is being sponsored by Cabot, Cabot & Forbes, a $5-billion enterprise sponsor from the Boston area. The sponsor has completed several other successful projects in the area including life sciences, office, multifamily and other commercial properties. 

You can find more details on this opportunity, as well as other current crowdfunding offerings on CrowdStreet’s investment platform.

Photo: courtesy of CrowdStreet.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.